Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Danaher Corp. pages available for free this week:
- Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Present Value of Free Cash Flow to Equity (FCFE)
- Debt to Equity since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
The financial ratios indicate a gradual improvement in the company’s leverage and debt management over the analyzed periods. The debt to equity ratio presents a consistent downward trend, decreasing from 0.84 in April 2020 to 0.32 by March 2025. This reduction suggests a deliberate strategy to reduce reliance on debt relative to shareholders' equity, enhancing financial stability.
Similarly, the debt to capital ratio follows a decreasing pattern, moving from 0.46 to 0.24 over the same timeframe. This confirms a reduction in the proportion of debt financing within the company's overall capital structure. The debt to assets ratio also declines steadily, from 0.38 to 0.21, implying a decrease in total liabilities proportionate to the company's asset base.
Financial leverage decreases from 2.22 to approximately 1.56, indicating a lower amplification of the equity base by debt. This decline reflects improved balance sheet conservatism and reduced risk exposure related to leverage.
The interest coverage ratio, available from the fourth quarter of 2020 onwards, shows significant improvement initially, rising from 17.35 to a peak of 41.32 in the fourth quarter of 2022. This indicates a strong ability to meet interest obligations from operating earnings. However, from that peak, the ratio gradually declines to 16.80 by the first quarter of 2025. Despite the decrease, the ratio remains well above initial values, signifying sustained strong interest coverage.
Overall, the data points to a consistent enhancement in the company’s debt profile and financial health, with reductions in various debt ratios alongside strong interest coverage levels. This trend suggests a focus on deleveraging and strengthening the capital structure, thereby potentially lowering financial risk and improving creditor confidence.
- Debt to Equity Ratio
- Decreased steadily from 0.84 to 0.32, reflecting lower leverage relative to equity.
- Debt to Capital Ratio
- Declined from 0.46 to 0.24, showing less dependence on debt within total capital.
- Debt to Assets Ratio
- Reduced from 0.38 to 0.21, indicating lower liabilities compared to assets.
- Financial Leverage
- Fell from 2.22 to around 1.56, demonstrating decreased use of debt to finance assets.
- Interest Coverage Ratio
- Increased notably from 17.35 to a peak of 41.32, then gradually declined to 16.80, maintaining a strong ability to cover interest expenses.
Debt Ratios
Coverage Ratios
Debt to Equity
Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | ||||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to equity1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Equity, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q1 2025 Calculation
Debt to equity = Total debt ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
-
The total debt shows a generally declining trend over the observed period, moving from $25,972 million in April 2020 down to $16,477 million by March 2025. There are some minor fluctuations, such as an increase from $20,423 million in July 2021 to $23,598 million in October 2021, and again from $19,875 million in June 2023 to $22,060 million in September 2023. However, the overall trajectory indicates a reduction in indebtedness, particularly noticeable after December 2023 when debt declined steadily from $18,402 million to $16,477 million by March 2025.
- Total Danaher Stockholders’ Equity
-
Stockholders' equity exhibits a general upward trend, increasing from $31,055 million in April 2020 to a peak around the end of 2023 at approximately $53,486 million. This growth is gradual and consistent, with small declines or plateaus observed between June 2024 and March 2025, where equity decreased from $53,442 million to $50,849 million. The increase in equity over the long term reflects strengthening shareholder value and potentially retained earnings or equity financing.
- Debt to Equity Ratio
-
The debt to equity ratio demonstrates a clear and sustained decrease, starting at 0.84 in April 2020 and falling to 0.32 by March 2025. This reduction indicates an improving financial leverage position, with the company progressively lowering its debt level relative to its equity base. Notably, the ratio fluctuates slightly around mid-2021 to late 2023, with short-term increases corresponding to temporary rises in debt levels, but the overall downward trend remains intact. The stabilization around 0.32 from late 2024 into early 2025 suggests the company may have reached a more conservative or targeted leverage ratio.
Debt to Capital
Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | ||||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | ||||||||||||||||||||||||||||
Total capital | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to capital1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Capital, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q1 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt exhibited a generally downward trend over the analyzed quarters. Starting at US$25,972 million in April 2020, it decreased to US$21,204 million by December 2020. Some fluctuations occurred in 2021, with debt rising to US$23,598 million in October before declining again. Through 2022 and into early 2023, total debt values remained relatively stable around the US$19,000 to US$20,000 million range. Notably, there was a spike to US$22,060 million in September 2023 followed by a significant decline to US$18,402 million by December 2023. The trend continued downward through 2024 and early 2025, reaching US$16,477 million in March 2025, representing an overall reduction in debt compared to the beginning of the period.
- Total Capital
- Total capital showed a mild increasing trend initially, starting at US$57,027 million in April 2020 and reaching a peak of US$74,467 million in September 2023. This represents a growth period through the middle of the examined timeframe, with intermittent declines such as from December 2023 onwards. After peaking in September 2023, total capital declined steadily to US$65,548 million by December 2024, before slightly recovering to US$67,326 million in March 2025. Despite the fluctuations, total capital remained consistently above the initial levels observed in early 2020.
- Debt to Capital Ratio
- The debt to capital ratio demonstrated a clear downward trajectory across the period under observation. Beginning at 0.46 in April 2020, this ratio declined steadily, reaching values below 0.30 as early as October 2021. It further decreased to around 0.24 by March 2025. This consistent reduction indicates an improving capital structure with a declining proportion of debt relative to total capital. The decrease in the ratio suggests enhanced financial leverage management and potentially a stronger equity base or retained earnings growth over time.
- Summary of Financial Trends
- Overall, the data reflect a strategic reduction of debt levels combined with stable to increasing total capital during most of the reported quarters. The resulting decline in the debt to capital ratio points to a strengthening balance sheet and a decrease in reliance on debt financing. Fluctuations in total debt in late 2023 correspond with temporary increases but the subsequent downward movement resumed, aligning with long-term deleveraging efforts. Total capital peaked near the end of 2023 but experienced some contraction in the following quarters, possibly indicating adjustments in capital structure or asset base. The consistent improvement in capital ratios suggests enhanced financial stability and potentially improved creditworthiness.
Debt to Assets
Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Notes payable and current portion of long-term debt | ||||||||||||||||||||||||||||
Long-term debt, excluding current portion | ||||||||||||||||||||||||||||
Total debt | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Debt to assets1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Debt to Assets, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q1 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- The total debt amount exhibits a general downward trend over the entire period. Starting at approximately $25.9 billion in April 2020, the debt declines notably to about $16.5 billion by March 2025. There are intermittent fluctuations, such as increases around October 2021 and September 2023, but the overall trajectory is decline. This suggests a consistent effort toward debt reduction or repayment over the five-year span.
- Total Assets
- Total assets show fluctuation but remain relatively stable in a narrow range. Beginning near $68.9 billion in April 2020, assets rise gradually, peaking around $87.7 billion by September 2023. Subsequently, there is a slight decrease toward the end of the timeline, settling near $79.1 billion in March 2025. This pattern indicates a period of asset growth followed by moderate contraction or rebalancing in recent quarters.
- Debt to Assets Ratio
- The debt to assets ratio shows a clear and steady decrease over time. Starting at 0.38 in April 2020, the ratio drops sharply through mid-2020 and continues a gradual descent, reaching around 0.21 by the end of the period in March 2025. This improvement in leverage ratio indicates strengthening financial stability, as the company's debt levels decline faster than its asset base, reducing financial risk.
- Overall Insights
- The data reflects a strategic shift toward lower leverage and enhanced financial solidity. The consistent reduction in total debt combined with relatively stable total assets leads to the declining debt to assets ratio, signifying improved balance sheet health. Short-term fluctuations in debt levels may correspond to financing activities or operational needs, but the dominant trend suggests prudent debt management practices aimed at strengthening the company’s capital structure over time.
Financial Leverage
Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Total Danaher stockholders’ equity | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Financial leverage1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Financial Leverage, Competitors2 | ||||||||||||||||||||||||||||
AbbVie Inc. | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q1 2025 Calculation
Financial leverage = Total assets ÷ Total Danaher stockholders’ equity
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends in the company’s asset base, equity, and leverage ratios over the examined periods.
- Total Assets
- Total assets displayed an upward trend from April 2020 through the end of 2021, increasing from approximately $68.9 billion to $83.2 billion. Beginning in early 2022, total assets fluctuated, peaking at about $84.35 billion at the close of 2022, then experiencing a general decline through 2024, reaching approximately $77.5 billion by the first quarter of 2025. This suggests a possible contraction or restructuring phase after a period of asset growth.
- Total Stockholders’ Equity
- Equity consistently rose from $31.1 billion in April 2020 to $51.5 billion by the end of the first quarter of 2025. The increase was relatively steady, with minor fluctuations, including a significant jump at the end of 2022. This indicates that shareholder value has been progressively built over the period, reflective of retained earnings growth or additional equity injections.
- Financial Leverage Ratio
- The leverage ratio showed a clear decreasing trend over the timeframe, starting at 2.22 in April 2020 and gradually declining to approximately 1.56 by the first quarter of 2025. This reduction suggests a stronger equity base relative to liabilities or a reduction in debt levels, indicating potentially lower financial risk and an improved capital structure.
In summary, the data portrays a company that expanded its asset base robustly until 2021 before experiencing some asset reductions. Equity steadily strengthened throughout, contributing to a declining leverage ratio. This combination points to enhanced financial stability and reduced reliance on debt over the analyzed periods.
Interest Coverage
Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | Dec 31, 2020 | Oct 2, 2020 | Jul 3, 2020 | Apr 3, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net earnings | ||||||||||||||||||||||||||||
Less: Earnings from discontinued operations, net of income taxes | ||||||||||||||||||||||||||||
Add: Income tax expense | ||||||||||||||||||||||||||||
Add: Interest expense | ||||||||||||||||||||||||||||
Earnings before interest and tax (EBIT) | ||||||||||||||||||||||||||||
Solvency Ratio | ||||||||||||||||||||||||||||
Interest coverage1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Interest Coverage, Competitors2 | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-10-02), 10-Q (reporting date: 2020-07-03), 10-Q (reporting date: 2020-04-03).
1 Q1 2025 Calculation
Interest coverage
= (EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024
+ EBITQ2 2024)
÷ (Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024
+ Interest expenseQ2 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The earnings before interest and tax (EBIT) demonstrate notable fluctuations over the analyzed periods. Starting from a lower point of 759 million USD in April 2020, EBIT rose sharply to peak at 2,141 million USD by April 2021. Subsequent quarters experienced volatility, with the EBIT decreasing in some periods and increasing in others, yet generally maintaining levels above 1,000 million USD. The highest values were observed in early 2021 and late 2022. Toward the end of the timeline, EBIT shows a downward trend with minor recoveries, reaching 1,201 million USD by March 2025.
Interest expense exhibits less dramatic variation but remains an important factor. Initially measured at 47 million USD, interest costs increased and fluctuated around the 50 to 85 million USD range throughout the timeframe. The peak interest expenses are observed in late 2023 and early 2024, with values near 85 million USD. This pattern suggests periodic rises in borrowing costs or changes in debt structure.
Interest coverage ratios indicate the company’s ability to meet its interest obligations through its EBIT. Coverage was not reported in the earliest periods but from December 2020 onward, there is a clear upward trend. The ratio started near 17 and improved steadily, peaking at over 41 in December 2022. After this peak, there is a noticeable decline in coverage, falling back to levels around 16-18 by early 2025. This pattern reflects improved profitability relative to interest costs during much of the period, with some erosion in the latest quarters potentially indicative of increasing interest burdens or declining operating profitability.
- EBIT trend
- Strong initial growth through 2021, fluctuating mid-cycle, followed by a declining trend toward 2025.
- Interest expense
- Generally stable with moderate fluctuations, peaking around late 2023 to early 2024.
- Interest coverage ratio
- Improved markedly from late 2020 through 2022, then declining but remaining above initial levels.
Overall, the data reveal a company showing growth and improved earnings capacity in the early part of the analyzed period, with increased efficiency in covering interest expenses. The recent decline in EBIT and coverage ratios signals potential emerging pressures on operational profitability or interest burden sustainability.